Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

BioMarin Pharmaceutical Inc. (BMRN)

91   -2 (-2.15%) 02-25 16:00
Open: 93.22 Pre. Close: 93
High: 93.7117 Low: 89.7
Volume: 1,699,442 Market Cap: 16346M
Biomarin Pharmaceutical Inc is on rare-disease therapies. It develops and commercializes pharmaceuticals for serious diseases and medical conditions.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 93.822 - 94.409 94.409 - 94.822
Low: 88.334 - 89.052 89.052 - 89.559
Close: 90.051 - 91.109 91.109 - 91.855

Technical analysis

as of: 2020-02-25 4:27:43 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 111.71     One year: 130.47
Support: Support1: 87.07    Support2: 81.78
Resistance: Resistance1: 95.64    Resistance2: 111.71
Pivot: 89.35
Moving Average: MA(5): 91.74     MA(20): 88.26
MA(100): 80.12     MA(250): 81.63
MACD: MACD(12,26): 1.65     Signal(9): 1.25
Stochastic oscillator: %K(14,3): 76.84     %D(3): 88.04
RSI: RSI(14): 57.15
52-week: High: 96.20  Low: 62.88  Change(%): -3.0
Average Vol(K): 3-Month: 125261  10-Days: 121512

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
BMRN has closed below upper band by 31.6%. Bollinger Bands are 9.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

BioMarin (BMRN) to Report Q4 Earnings: What's in the Cards?
Key orphan disease drugs, Vimizim and Kuvan, are likely to have driven BioMarin's (BMRN) fourth-quarter top line.

BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020
SAN RAFAEL, Calif., Feb. 20, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) to the FDA for its investigational AAV5 gene therapy,…

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 179.62
Shares Float (M) 178.50
% Held by Insiders 0.49
% Held by Institutions 98.43
Shares Short (K) 8700
Shares Short P. Month (K)

Stock Financials

EPS -0.240
Book Value (p.s.) 17.120
PEG Ratio -3.72
Profit Margin -2.65
Operating Margin -9.69
Return on Assets (ttm) -2.1
Return on Equity (ttm) -1.4
Qtrly Rev. Growth 17.7
Gross Profit (p.s.) 2.670
Sales Per Share
EBITDA (p.s.) -0.284
Qtrly Earnings Growth
Operating Cash Flow (M) 40.29
Levered Free Cash Flow (M) -104.34

Stock Valuations

P/E -379.17
P/E Growth Ratio -0.02
P/BV 5.32
P/S 10.14
P/CF 405.69

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.